Verified pilot-scale capabilities delivering cost-effective phytochemical discovery, analytical standardization, and commercial OEM batch production.
High-throughput cellular and enzyme assays quantifying bioactivity early to minimize downstream preclinical capital burn.
In Vitro Service Specs →
GLP-aligned in vivo pharmacodynamics and toxicological screening generating robust dossier data at domestic operating costs.
Animal Study Details →
Chromatographic fingerprinting, HPLC/GC-MS, and HPTLC standard setting ensuring reproducible batch purity and validation.
Analytical Method Protocols →
Turnkey multi-center clinical trials, bioequivalence protocols, and GCP compliance for hospital preparation and NDA filings.
Clinical Study Protocols →
Computational and bio-directed fractionation isolating high-potency monomer fractions from natural botanical matrices.
Screening Solutions →
Multi-origin seasonal metabolomic profiling to maximize active yield and stabilize long-term bulk procurement expenditure.
Origin Study Report →
Commercial solvent recovery, molecular distillation, and supercritical fluid extraction scaling from grams to metric tons.
Bulk API Production →
GMP manufacturing for finished oral liquids, micro-tablets, softgels, capsules, and sachet granules with clean labels.
Dosage Form Manufacturing →Why modern life science companies are replacing siloed procurement with synchronized CRO/CDMO integration to drive competitive advantages.
Traditional procurement conflates Cost-Effectiveness with low spot quotation. However, hidden costs typically surface later via batch rejections, solvent impurities, analytical drift, and delayed regulatory clearance.
A genuinely cost-effective OEM partner mitigates Total Cost of Ownership (TCO) through precision-engineered extraction parameters, zero-defect process design, and verified yield stability at inception.
Over 60% of natural chemical development stalls when translating benchtop chromatography to multi-ton crystallization. Transferring files between independent research vendors and factories leads to intellectual loss and capital attrition.
By housing analytical method development, toxicology testing, and commercial extraction suites under one technological roof, our unified model eliminates re-engineering expenses.
A formulation lacking validated analytical identification or certified safety profiles incurs significant post-launch liability. Compliance is an essential pillar of financial prudence.
Standardizing active components with HPTLC fingerprinting and validating genotoxicity/LD50 benchmarks shields global brand owners from costly product recalls and friction across diverse customs jurisdictions.
Quantifying real-world lifecycle efficiencies achieved when migrating from traditional brokered sourcing to our integrated contract development architecture:
| Performance Metric | Conventional Dispersed Sourcing | MedGence Integrated CRO/CDMO Framework | Enterprise ROI Impact |
|---|---|---|---|
| Lead Time to Clinical Pilot | 14–22 Months (Handover delays across 3+ entities) | 5–8 Months (In-house laboratory to pilot line) | 62% Acceleration to Market |
| Analytical Validation Friction | High inter-laboratory variance; cross-validation costs | Standardized HPLC/HPTLC protocols built-in | Zero Secondary Protocol Verification Costs |
| Raw Botanical Supply Variance | Spot market volatility; unpredictable seasonal potency | Origin-Mapped Geospatial Sourcing & contracts | 28–34% Reduced Raw Active Waste |
| Regulatory Batch Failure Risk | Estimated 8–15% re-assay and quarantine risk | Under 0.2% (Controlled closed-loop GMP validation) | Protection against catastrophic inventory write-offs |
How centralizing botanical extraction in China combines geographical raw material superiority with modern engineering and localized regulatory compliance.
China is home to over 11,000 medicinal plant varieties. Operating our core R&D hub in Changsha, Hunan, provides immediate proximity to primary botanical regions across central and southwestern China.
Our localized research evaluates phytochemical density across different seasons, altitudes, and harvest times. Securing biomass directly from farm cooperatives removes multilayer broker margins while guaranteeing batch-to-batch chemical integrity.
Cross-border procurement often falters on documentation rather than chemistry. Our facilities operate within a dual-framework compliance system aligned with global pharmacopeias.
We supply complete analytical dossier support: heavy metal assays via ICP-MS, residual solvent analysis (USP <467>), pesticide screens (USP <561>), and stability data packages satisfying US FDA 21 CFR Part 111, European Pharmacopoeia (Ph. Eur.), and China NMPA hospital preparation standards.
Bridging language, time-zone, and technical barriers is critical for smooth project execution. Our international service desks provide dedicated bilingual scientific program managers.
Clients receive real-time visibility into extraction metrics, chromatographic runs, and animal trials. In addition, our team handles customs re-classification declarations, HS-code tariff optimization, and certified certificates of analysis (COA) to streamline port clearance.
The industrial park footprint in China offers an integrated supply of specialized laboratory gear, continuous countercurrent extraction vessels, vacuum freeze dryers, and high-speed encapsulation machinery.
This deep industrial network allows us to expand manufacturing campaigns within weeks rather than months, absorbing sudden volume spikes from expanding international consumer brands without steep surcharges.
How distinct business segments translate our natural CRO/CDMO services into commercial market success.
Procurement Objective: Verified functional benefits with verified absence of adulterants, solvent residues, and microbiological contaminants at high unit margins.
Our Solution: Standardized spray-dried powders and microencapsulated extracts designed for clean-label premixes, backed by human cell line antioxidant/anti-inflammatory data.
Procurement Objective: Patented botanical actives that demonstrate measurable barrier-repair, tyrosinase inhibition, or collagen synthesis without skin sensitization.
Our Solution: High-purity polyphenol and triterpenoid fractions supported by certified 3D human skin model in vitro assays and OECD 404 dermal irritation documentation.
Procurement Objective: Rigorous chemistry, manufacturing, and controls (CMC) packages satisfying investigational drug requirements at predictable milestones.
Our Solution: Full Phase I–IV clinical program design, validated TCM compound modernizations, and hospital preparation registrations (56 approvals secured to date).
Anticipating structural regulatory and technological shifts to keep your product lines ahead of international competition.
Machine-learning models query metabolomic datasets to forecast seasonal phyto-yields and predict extraction bottlenecks before initial processing.
Phasing out harsh hydrocarbons in favor of subcritical water and closed-loop CO2 extraction to align with international clean-solvent mandates.
Next-generation DNA barcoding deployed alongside HPLC to eliminate adulteration and unrecorded species blending from early botanical feeds.
Streamlined Phase I-II study designs that combine remote biological telemetry with localized clinic trials to reduce cost-per-patient hurdles.
Clear, direct answers to common questions about international supply chain integration, testing workflows, and intellectual property.
Fragmented sourcing forces you to pay overhead across separate discovery labs, analytical houses, pilot plants, and formulation facilities. Each handoff adds project delays and testing fees. MedGence integrates testing, extraction design, and batch manufacturing in one location, removing redundant cross-validation and cutting development timelines by 40–60%.
We work exclusively on an entrusted research and manufacturing model. All client work is backed by strict bilateral non-disclosure agreements, segmented database controls, and dedicated pilot batch isolation. Your formulations, purification methods, and clinical data remain your exclusive intellectual property.
Our centralized testing centers utilize Waters and Agilent HPLC systems, GC-MS setups for residual solvent testing, HPTLC digital imaging for identity authentication, and ICP-MS for trace heavy metal detection. Every release batch includes a full certificate of analysis aligned with USP, EP, or ChP standards.
Yes. Our regulatory affairs team assists with dossiers for US FDA NDI (New Dietary Ingredient) notifications, European Union Novel Food applications, and China NMPA Hospital Preparation registrations, drawing on our portfolio of 56 registered formulations.
For research, analytical method development, and in vitro screening, we accept gram-scale requirements. For pilot trials, batch sizes run from 5 kg to 50 kg. Full commercial production lines accommodate bulk raw botanical processing ranging from 500 kg to multi-ton container shipments.
We conduct metabolomic finger-printing across multiple agricultural harvesting zones and seasons. This identifies when and where targeted phyto-actives peak in the plant, allowing us to lock in supplies when active content is highest and optimize extraction costs.
Review standard and custom study plans or connect directly with our engineering teams to review specifications.
Cell culture, receptor binding, and mechanistic assay solutions designed to validate target bioactivity before pilot synthesis.
Request Test Quotation →
In vivo efficacy profiling, metabolic monitoring, and toxicology in validated small animal models to build preclinical dossiers.
Order Preclinical Study →
Full analytical method development, system suitability verification, and transfer protocols for accurate phytochemical assays.
Establish Analytical QC →
Full human clinical study management, trial documentation, and institutional ethics committee coordination for NDA filings.
Scope Clinical Trial →
Targeted bio-fractionation identifying primary active constituents across traditional Chinese herbs and raw plant materials.
Discover Plant Actives →
Metabolomic screening across varying harvest times and geographical origins to identify raw materials with the highest active yields.
Evaluate Plant Terroirs →
Preclinical safety profiles meeting global health authority requirements: Ames tests, micronucleus assays, and repeat-dose studies.
Toxicity Testing Packages →
Custom multi-herb formulation matching, pharmacokinetic balance, stability testing, and modern finished-dose formulation.
Start Formulation Project →